These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 3663509)
1. Antithrombin III Glasgow: a variant with increased heparin affinity and reduced ability to inactivate thrombin, associated with familial thrombosis. Lane DA; Lowe GD; Flynn A; Thompson E; Ireland H; Erdjument H Br J Haematol; 1987 Aug; 66(4):523-7. PubMed ID: 3663509 [TBL] [Abstract][Full Text] [Related]
2. Antithrombin III Northwick Park: demonstration of an inactive high MW complex with increased affinity for heparin. Lane DA; Flynn A; Ireland H; Erdjument H; Samson D; Howarth D; Thompson E Br J Haematol; 1987 Apr; 65(4):451-6. PubMed ID: 3580302 [TBL] [Abstract][Full Text] [Related]
3. Antithrombin III Kumamoto II; a single mutation at Arg393-His increased the affinity of antithrombin III for heparin. Okajima K; Abe H; Wagatsuma M; Okabe H; Takatsuki K Am J Hematol; 1995 Jan; 48(1):12-8. PubMed ID: 7832187 [TBL] [Abstract][Full Text] [Related]
4. An abnormal antithrombin III (AT III) with low heparin affinity: AT III Clichy. Aiach M; François D; Priollet P; Capron L; Roncato M; Alhenc-Gelas M; Fiessinger JN Br J Haematol; 1987 Aug; 66(4):515-22. PubMed ID: 3663508 [TBL] [Abstract][Full Text] [Related]
5. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding. Jørgensen M; Petersen LC; Thorsen S J Lab Clin Med; 1984 Aug; 104(2):245-56. PubMed ID: 6747440 [TBL] [Abstract][Full Text] [Related]
6. Homozygous variant of antithrombin III that lacks affinity for heparin, AT III Kumamoto. Okajima K; Ueyama H; Hashimoto Y; Sasaki Y; Matsumoto K; Okabe H; Inoue M; Araki S; Takatsuki K Thromb Haemost; 1989 Feb; 61(1):20-4. PubMed ID: 2749590 [TBL] [Abstract][Full Text] [Related]
7. A functional abnormal antithrombin III (AT III) deficiency: AT III Charleville. Aiach M; Nora M; Fiessinger JN; Roncato M; François D; Gelas MA Thromb Res; 1985 Sep; 39(5):559-70. PubMed ID: 4082101 [TBL] [Abstract][Full Text] [Related]
8. Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administration. Collen D; Schetz J; de Cock F; Holmer E; Verstraete M Eur J Clin Invest; 1977 Feb; 7(1):27-35. PubMed ID: 65284 [TBL] [Abstract][Full Text] [Related]
9. Antithrombin Glasgow, 393 Arg to His: a P1 reactive site variant with increased heparin affinity but no thrombin inhibitory activity. Owen MC; Beresford CH; Carrell RW FEBS Lett; 1988 Apr; 231(2):317-20. PubMed ID: 3360140 [TBL] [Abstract][Full Text] [Related]
10. Antithrombin Sheffield: amino acid substitution at the reactive site (Arg393 to His) causing thrombosis. Lane DA; Erdjument H; Flynn A; Di Marzo V; Panico M; Morris HR; Greaves M; Dolan G; Preston FE Br J Haematol; 1989 Jan; 71(1):91-6. PubMed ID: 2917133 [TBL] [Abstract][Full Text] [Related]
11. Antithrombin Glasgow II: alanine 382 to threonine mutation in the serpin P12 position, resulting in a substrate reaction with thrombin. Ireland H; Lane DA; Thompson E; Walker ID; Blench I; Morris HR; Freyssinet JM; Grunebaum L; Olds R; Thein SL Br J Haematol; 1991 Sep; 79(1):70-4. PubMed ID: 1911389 [TBL] [Abstract][Full Text] [Related]
12. Deletion of P1 arginine in a novel antithrombin variant (antithrombin London) abolishes inhibitory activity but enhances heparin affinity and is associated with early onset thrombosis. Raja SM; Chhablani N; Swanson R; Thompson E; Laffan M; Lane DA; Olson ST J Biol Chem; 2003 Apr; 278(16):13688-95. PubMed ID: 12591924 [TBL] [Abstract][Full Text] [Related]
14. Heparin cofactor activities in a family with hereditary antithrombin III deficiency: evidence for a second heparin cofactor in human plasma. Griffith MJ; Carraway T; White GC; Dombrose FA Blood; 1983 Jan; 61(1):111-8. PubMed ID: 6184096 [TBL] [Abstract][Full Text] [Related]
15. Homozygous variant of antithrombin III: AT III Fontainebleau. Boyer C; Wolf M; Vedrenne J; Meyer D; Larrieu MJ Thromb Haemost; 1986 Aug; 56(1):18-22. PubMed ID: 3775688 [TBL] [Abstract][Full Text] [Related]
16. Antithrombin-III-Hamilton, Ala 382 to Thr: an antithrombin-III variant that acts as a substrate but not an inhibitor of alpha-thrombin and factor Xa. Austin RC; Rachubinski RA; Ofosu FA; Blajchman MA Blood; 1991 May; 77(10):2185-9. PubMed ID: 2029579 [TBL] [Abstract][Full Text] [Related]
17. Antithrombin III Geneva: a hereditary abnormal AT III with defective heparin cofactor activity. de Moerloose PA; Reber G; Vernet P; Minazio P; Bouvier CA Thromb Haemost; 1987 Apr; 57(2):154-7. PubMed ID: 3603409 [TBL] [Abstract][Full Text] [Related]
18. Antithrombin III Nagasaki (Ser116-Pro): a heterozygous variant with defective heparin binding associated with thrombosis. Okajima K; Abe H; Maeda S; Motomura M; Tsujihata M; Nagataki S; Okabe H; Takatsuki K Blood; 1993 Mar; 81(5):1300-5. PubMed ID: 8443391 [TBL] [Abstract][Full Text] [Related]
19. Immunoelectrophoretic evidence of a thrombin-induced abnormality in a new variant of hereditary dysfunctional antithrombin III (AT III 'Vicenza'). Barbui T; Finazzi G; Rodeghiero F; Dini E Br J Haematol; 1983 Aug; 54(4):561-5. PubMed ID: 6871107 [TBL] [Abstract][Full Text] [Related]
20. Isolation and characterization of an antithrombin III variant with reduced carbohydrate content and enhanced heparin binding. Peterson CB; Blackburn MN J Biol Chem; 1985 Jan; 260(1):610-5. PubMed ID: 3965464 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]